A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis

Phase 3

Terminated

Conditions: Psoriasis

Interventions: Drug: CP-690,550

Registration Number: NCT01163253

Lead Sponsor: Pfizer

Brief Summary: The main objective of this study is to evaluate the long-term safety of CP-690,550 in patients being treated for moderate to severe chronic plaque psoriasis. This is an open label extension study available to patients who participated in one of the qualifying studies with CP-690,550 providing entry criteria is met.

Detailed Description: The study terminated on 08MAR2016 as it met its objectives of characterizing long term safety and tolerability. The study did not terminate due to safety concerns.

Recruitment & Eligibility

Status: TERMINATED

Sex: All

Target Recruitment: 2867

Inclusion Criteria

Have participated in qualifying study with CP-690,550 and are 18 years or older with diagnosis of plaque-type psoriasis (psoriasis vulgaris).

Exclusion Criteria

Non-plaque or drug induced forms of psoriasis;
Cannot discontinue current oral, injectable or topical therapy for psoriasis or cannot discontinue phototherapy (PUVA or UVB).
Any uncontrolled significant medical condition.

Study & Design

Study Type: INTERVENTIONAL

Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Active Treatment	CP-690,550	The study is anticipated to continue for up to at least 2 years post First Market Approval (FMA) in a global, major market. All subjects will receive 10 mg BID of CP-690,550 for first 3 months of trial. Study has the option for variable dosing with 5 mg or 10 mg BID after first 3-months of treatment based on PI discretion

Primary Outcome Measures

Name	Time	Method
Change From Baseline in Lymphocyte and Neutrophil Count at Month 3	Baseline, Month 3
Change From Baseline in Lymphocyte and Neutrophil Count at Month 24	Baseline, Month 24
Change From Baseline in Heart Rate at Month 48	Baseline, Month 48
Change From Baseline in Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) Levels at Month 36	Baseline, Month 36
Change From Baseline in Hemoglobin Level at Month 1	Baseline, Month 1
Change From Baseline in Lymphocyte and Neutrophil Count at Month 12	Baseline, Month 12
Change From Baseline in Creatinine, Low Density Lipoprotein Cholesterol (LDL-C), High Density Lipoprotein Cholesterol (HDL-C) and Total Cholesterol (TC) Levels at Month 3	Baseline, Month 3
Change From Baseline in Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) Levels at Month 12	Baseline, Month 12
Change From Baseline in Systolic Blood Pressure (BP) and Diastolic BP at Month 3	Baseline, Month 3
Number of Adverse Events (AEs) by Severity	Baseline up to 4 weeks after last dose of study drug (up to a maximum of 67 months)	An AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. AEs were classified according to the severity in 3 categories: a) mild: AEs did not interfere with participant's usual function; b) moderate: AEs interfered to some extent with participant's usual function; c) severe: AEs interfered significantly with participant's usual function.
Change From Baseline in Lymphocyte and Neutrophil Count at Month 1	Baseline, Month 1
Change From Baseline in Hemoglobin Level at Month 6	Baseline, Month 6
Change From Baseline in Hemoglobin Level at Month 36	Baseline, Month 36
Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)	Baseline up to 4 weeks after last dose of study drug (up to a maximum of 67 months)	An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events between first dose of study drug and up to 4 weeks after last dose (up to 67 months) that were absent before treatment or that worsened relative to pretreatment state. AEs included both serious and non-serious adverse events.
Change From Baseline in Lymphocyte and Neutrophil Count at Month 6	Baseline, Month 6
Change From Baseline in Lymphocyte and Neutrophil Count at Month 36	Baseline, Month 36
Change From Baseline in Lymphocyte and Neutrophil Count at Month 48	Baseline, Month 48
Change From Baseline in Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) Levels at Month 48	Baseline, Month 48
Change From Baseline in Systolic Blood Pressure (BP) and Diastolic BP at Month 6	Baseline, Month 6
Number of Participants With Laboratory Abnormalities	Baseline up to 4 weeks after last dose of study drug (up to a maximum of 67 months)	Abnormality criteria: hematology (hemoglobin, hematocrit, red blood cell \<0.8\lower limit of normal \[LLN\]; reticulocyte\<0.5\LLN,\>1.5\ULN; platelets\<0.5\LLN,\>1.75\* upper limit of normal \[ULN\]; WBC\<0.6\LLN, \>1.5\ULN; lymphocytes, neutrophils, basophils, eosinophils, monocytes\<0.8\LLN; \>1.2\ULN; coagulation (prothrombin \[PT\], PT ratio\>1.1\ULN) liver function (bilirubin\>1.5\ULN, aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, gamma GT\>0.3\ULN, protein, albumin\<0.8\LLN; \>1.2\ULN, globulin\<0.5\LLN; \>1.5\ULN); renal function (blood urea nitrogen, creatinine\>1.3\ULN); electrolytes(sodium\<0.95\* LLN; \>1.05\* ULN, potassium, chloride, calcium, bicarbonate\<0.9\LLN; \>1.1\ULN), chemistry (glucose\<0.6\LLN; \>1.5\ ULN), urinalysis (pH \<4.5;\>8, glucose, ketones, protein, blood, urobilinogen, nitrite, bilirubin, leukocyte esterase\>=1; RBC, WBC\>=20); lipids (cholesterol \[C\], LDL-C \>1.3\ULN, HDL-C\<0.8\LLN, triglycerides\>1.3\* ULN), hormones(T4, T3, T4, TSH\<0.8\* LLN; \>1.2\* ULN).
Change From Baseline in Hemoglobin Level at Month 3	Baseline, Month 3
Change From Baseline in Hemoglobin Level at Month 12	Baseline, Month 12
Change From Baseline in Hemoglobin Level at Month 24	Baseline, Month 24
Change From Baseline in Hemoglobin Level at Month 48	Baseline, Month 48
Change From Baseline in Creatinine, Low Density Lipoprotein Cholesterol (LDL-C), High Density Lipoprotein Cholesterol (HDL-C) and Total Cholesterol (TC) Levels at Month 1	Baseline, Month 1
Change From Baseline in Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) Levels at Month 3	Baseline, Month 3
Change From Baseline in Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) Levels at Month 6	Baseline, Month 6
Number of Participants With Clinically Significant Change From Baseline in Physical Examination	Baseline up to 4 weeks after last dose of study drug (up to a maximum of 67 months)	Physical examinations included: general appearance; skin, head, eyes, ears, nose and throat; heart; lungs; abdomen; lower extremities (for the presence of peripheral edema) and lymph nodes. Clinical significance of change from baseline values in physical examination was based on investigator's discretion.
Change From Baseline in Creatinine, Low Density Lipoprotein Cholesterol (LDL-C), High Density Lipoprotein Cholesterol (HDL-C) and Total Cholesterol (TC) Levels at Month 24	Baseline, Month 24
Change From Baseline in Creatinine, Low Density Lipoprotein Cholesterol (LDL-C), High Density Lipoprotein Cholesterol (HDL-C) and Total Cholesterol (TC) Levels at Month 36	Baseline, Month 36
Change From Baseline in Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) Levels at Month 1	Baseline, Month 1
Change From Baseline in Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) Levels at Month 24	Baseline, Month 24
Change From Baseline in Heart Rate at Month 6	Baseline, Month 6
Change From Baseline in Creatinine, Low Density Lipoprotein Cholesterol (LDL-C), High Density Lipoprotein Cholesterol (HDL-C) and Total Cholesterol (TC) Levels at Month 6	Baseline, Month 6
Change From Baseline in Creatinine, Low Density Lipoprotein Cholesterol (LDL-C), High Density Lipoprotein Cholesterol (HDL-C) and Total Cholesterol (TC) Levels at Month 12	Baseline, Month 12
Change From Baseline in Creatinine, Low Density Lipoprotein Cholesterol (LDL-C), High Density Lipoprotein Cholesterol (HDL-C) and Total Cholesterol (TC) Levels at Month 48	Baseline, Month 48
Change From Baseline in Systolic Blood Pressure (BP) and Diastolic BP at Month 1	Baseline, Month 1
Change From Baseline in Systolic Blood Pressure (BP) and Diastolic BP at Month 24	Baseline, Month 24
Change From Baseline in Heart Rate at Month 1	Baseline, Month 1
Change From Baseline in Heart Rate at Month 24	Baseline, Month 24
Change From Baseline in QRS Complex, PR, QT, QTcB, QTcF and RR Interval at Month 12	Baseline, Month 12
Number of Participants With Adjudicated Cardiovascular Events	Baseline up to 4 weeks after last dose of study drug (up to a maximum of 67 months)	Adjudicated cardiovascular events were assessed by adjudication committee as independent reviewers based on event documentation including: hospital discharge summaries, operative reports, clinic notes, ECGs, diagnostic enzymes, results of other diagnostic tests, autopsy reports and death certificate information; as applicable.
Number of Participants With Vital Sign Abnormalities	Baseline up to 4 weeks after last dose of study drug (up to a maximum of 67 months)	Criteria for abnormalities in vital signs included: Systolic blood pressure (SBP): less than (\<) 90 millimeter of mercury (mmHg) and maximum increase from baseline (IFB) of greater than or equal to (\>=) 30 mmHg; diastolic blood pressure (DBP): \<50 and greater than (\>) 120 mmHg and maximum IFB of \>=20 mmHg; heart rate: \<40 and \>120 beats per minute.
Change From Baseline in Systolic Blood Pressure (BP) and Diastolic BP at Month 36	Baseline, Month 36
Change From Baseline in Heart Rate at Month 36	Baseline, Month 36
Change From Baseline in QRS Complex, PR, QT, QTcB, QTcF and RR Interval at Month 24	Baseline, Month 24
Change From Baseline in QRS Complex, PR, QT, QTcB, QTcF and RR Interval at Month 36	Baseline, Month 36
Change From Baseline in Systolic Blood Pressure (BP) and Diastolic BP at Month 12	Baseline, Month 12
Change From Baseline in Heart Rate at Month 12	Baseline, Month 12
Number of Participants With Electrocardiogram (ECG) Abnormalities	Baseline up to 4 weeks after last dose of study drug (up to a maximum of 67 months)	Criteria for ECG abnormality: PR interval \>=300 milliseconds (msec); QT interval \>=500 msec; QTcB (Bazett's Correction) and QTcF (Fridericia's Correction) 450 to \<480 msec, 480 to \<500 msec and \>=500 msec.
Change From Baseline in QRS Complex, PR, QT, QTcB, QTcF and RR Interval at Month 48	Baseline, Month 48
Change From Baseline in Systolic Blood Pressure (BP) and Diastolic BP at Month 48	Baseline, Month 48
Change From Baseline in Heart Rate at Month 3	Baseline, Month 3
Change From Baseline in QRS Complex, PR, QT, QTcB, QTcF and RR Interval at Month 6	Baseline, Month 6
Number of Participants With Malignancy Events	Baseline up to 4 weeks after last dose of study drug (up to a maximum of 67 months)	Malignancy events included lymphoma, and demyelinating neurologic events. Biopsies collected for malignancy events were submitted to the central laboratory for pathologist over-read.

Secondary Outcome Measures

Name	Time	Method
Psoriasis Area and Severity Index (PASI) Scores	Baseline, Month 1, 3, 6, 12, 24, 36, 48	PASI score is the combined assessment of lesion severity (estimated by 3 components: of erythema, induration and scaling) and area affected into single score range: 0 (no disease) to 72 (maximal disease), with higher scores representing greater severity of psoriasis. Each component of severity, that is, erythema, induration and scaling was assessed separately for four body areas (head and neck \[h\], upper limbs \[u\], trunk \[t\] and lower limbs \[l\]) on a 5-point scale ranging from 0=no involvement, 1=slight, 2=moderate, 3=marked, 4=very marked. Higher score indicates greater severity. Final PASI score = 0.1Ah (Eh + Ih + Sh) + 0.2Au (Eu + Iu + Su) + 0.3At (Et + It + St) + 0.4Al (El + Il + Sl), where head and neck: 0.1; upper limbs: 0.2; trunk: 0.3; lower limbs: 0.4.
Change From Baseline in Psoriasis Area and Severity Index (PASI) Scores at Month 1, 3, 6, 12, 24, 36 and 48	Baseline, Month 1, 3, 6, 12, 24, 36, 48	PASI score is the combined assessment of lesion severity (estimated by 3 components: of erythema, induration and scaling) and area affected into single score range: 0 (no disease) to 72 (maximal disease), with higher scores representing greater severity of psoriasis. Each component of severity, that is, erythema, induration and scaling was assessed separately for four body areas (head and neck \[h\], upper limbs \[u\], trunk \[t\] and lower limbs \[l\]) on a 5-point scale ranging from 0=no involvement, 1=slight, 2=moderate, 3=marked, 4=very marked. Higher score indicates greater severity. Final PASI score = 0.1Ah (Eh + Ih + Sh) + 0.2Au (Eu + Iu + Su) + 0.3At (Et + It + St) + 0.4Al (El + Il + Sl), where head and neck: 0.1; upper limbs: 0.2; trunk: 0.3; lower limbs: 0.4.
Psoriasis Area and Severity Index (PASI) Component Scores: Erythema	Baseline, Month 1, 3, 6, 12, 24, 36, 48	PASI score is the combined assessment of lesion severity (estimated by 3 components: of erythema, induration and scaling) and area affected into single score range: 0 (no disease) to 72 (maximal disease), with higher scores representing greater severity of psoriasis. Erythema was assessed separately for four body areas (head and neck, upper limbs, trunk and lower limbs) on a 5-point scale ranges from 0=no involvement, 1=slight, 2=moderate, 3=marked, 4=very marked. Higher score indicates greater severity.
Itch Severity Item (ISI) Scores	Baseline, Month 1, 3, 6, 12, 24, 36, 48	ISI assessed severity of itching due to psoriasis. ISI was a single item, horizontal numeric rating scale. Participants were asked to rate their 'severity of itching' due to psoriasis over the past 24 hours on a numeric rating scale anchored by the terms '0=no itching' and '10=worst possible itching' at the ends. Higher scores indicated greater severity of itching.
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores: Induration at Month 1, 3, 6, 12, 24, 36 and 48	Baseline, Month 1, 3, 6, 12, 24, 36, 48	PASI score is the combined assessment of lesion severity (estimated by 3 components: of erythema, induration and scaling) and area affected into single score range: 0 (no disease) to 72 (maximal disease), with higher scores representing greater severity of psoriasis. Induration was assessed separately for four body areas (head and neck, upper limbs, trunk and lower limbs) on a 5-point scale ranges from 0=no involvement, 1=slight, 2=moderate, 3=marked, 4=very marked. Higher score indicates greater severity.
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores: Scaling at Month 1, 3, 6, 12, 24, 36 and 48	Baseline, Month 1, 3, 6, 12, 24, 36, 48	PASI score is the combined assessment of lesion severity (estimated by 3 components: of erythema, induration and scaling) and area affected into single score range: 0 (no disease) to 72 (maximal disease), with higher scores representing greater severity of psoriasis. Scaling was assessed separately for four body areas (head and neck, upper limbs, trunk and lower limbs) on a 5-point scale ranges from 0=no involvement, 1=slight, 2=moderate, 3=marked, 4=very marked. Higher score indicates greater severity.
Percentage of Participants Achieving Greater Than or Equal to (>=) 90 Percent Reduction From Baseline in Psoriasis Area and Severity Index (PASI) Scores	Baseline, Month 1, 3, 6, 12, 24, 36, 48	PASI score is the combined assessment of lesion severity (estimated by 3 components: of erythema, induration and scaling) and area affected into single score range: 0 (no disease) to 72 (maximal disease), with higher scores representing greater severity of psoriasis. Each component of severity, that is, erythema, induration and scaling was assessed separately for four body areas (head and neck \[h\], upper limbs \[u\], trunk \[t\] and lower limbs \[l\]) on a 5-point scale ranging from 0=no involvement, 1=slight, 2=moderate, 3=marked, 4=very marked. Higher score indicates greater severity. Final PASI score = 0.1Ah (Eh + Ih + Sh) + 0.2Au (Eu + Iu + Su) + 0.3At (Et + It + St) + 0.4Al (El + Il + Sl), where head and neck: 0.1; upper limbs: 0.2; trunk: 0.3; lower limbs: 0.4. Percentage of participants with \>=90% reduction from baseline in PASI scores were reported.
Change From Baseline in Itch Severity Item (ISI) Scores at Month 1, 3, 6, 12, 24, 36 and 48	Baseline, Month 1, 3, 6, 12, 24, 36, 48	ISI assessed severity of itching due to psoriasis. ISI was a single item, horizontal numeric rating scale. Participants were asked to rate their 'severity of itching' due to psoriasis over the past 24 hours on a numeric rating scale anchored by the terms '0=no itching' and '10=worst possible itching' at the ends. Higher scores indicated greater severity of itching.
Change From Baseline in Dermatology Life Quality Index (DLQI) Scores at Month 1, 6, 12, 24, 36 and 48	Baseline, Month 1, 6, 12, 24, 36, 48	The DLQI was a validated, self-administered, 10-item quality-of-life questionnaire that consisted of 10 items that assessed the impact of skin disease on quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). Each question was scored on a scale of 0=not at all/not relevant to 3=very much. Response from all of the 10 questions were added to derive the DLQI total scores. Total DLQI scores ranges from 0=not at all to 30=very much, with higher scores indicating greater impairment in quality of life.
Percentage of Participants Achieving Physician Global Assessment (PGA) Response of 'Clear' or 'Almost Clear'	Month 1, 3, 6, 12, 24, 36, 48	The PGA of psoriasis was scored on a 5-point scale, reflecting a global consideration of the erythema (E), induration (I), and scaling (S) across all psoriatic lesions in participants. The severity rating scores (Erythema: 0= no evidence of erythema to 4= dark, deep red; Induration: 0= no evidence of plaque elevation to 4= marked plaque elevation, hard/sharp borders; Scaling: 0= no evidence of scaling to 4= thick, coarse scale predominates) were summed (E + I + S = total) and the average (total/3) was taken. The total average was rounded to the nearest whole number score to determine the PGA. The 5-point scale for PGA was: 0= clear; 1= almost clear; 2= mild; 3= moderate; 4= severe, where higher score indicated more severity of psoriasis. Percentage of participants with response of 'clear' (score of '0') and 'almost clear' (score of '1') were reported.
Psoriasis Area and Severity Index (PASI) Component Scores: Scaling	Baseline, Month 1, 3, 6, 12, 24, 36, 48	PASI score is the combined assessment of lesion severity (estimated by 3 components: of erythema, induration and scaling) and area affected into single score range: 0 (no disease) to 72 (maximal disease), with higher scores representing greater severity of psoriasis. Scaling was assessed separately for four body areas (head and neck, upper limbs, trunk and lower limbs) on a 5-point scale ranges from 0=no involvement, 1=slight, 2=moderate, 3=marked, 4=very marked. Higher score indicates greater severity.
Dermatology Life Quality Index (DLQI) Scores	Baseline, Month 1, 6, 12, 24, 36, 48	The DLQI was a validated, self-administered, 10-item quality-of-life questionnaire that consisted of 10 items that assessed the impact of skin disease on quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). Each question was scored on a scale of 0=not at all/not relevant to 3=very much. Response from all of the 10 questions were added to derive the DLQI total scores. Total DLQI scores ranges from 0=not at all to 30=very much, with higher scores indicating greater impairment in quality of life.
Percentage of Participants Achieving Greater Than or Equal to (>=) 75 Percent Reduction From Baseline in Psoriasis Area and Severity Index (PASI) Scores	Baseline, Month 1, 3, 6, 12, 24, 36, 48	PASI score is the combined assessment of lesion severity (estimated by 3 components: of erythema, induration and scaling) and area affected into single score range: 0 (no disease) to 72 (maximal disease), with higher scores representing greater severity of psoriasis. Each component of severity, that is, erythema, induration and scaling was assessed separately for four body areas (head and neck \[h\], upper limbs \[u\], trunk \[t\] and lower limbs \[l\]) on a 5-point scale ranging from 0=no involvement, 1=slight, 2=moderate, 3=marked, 4=very marked. Higher score indicates greater severity. Final PASI score = 0.1Ah (Eh + Ih + Sh) + 0.2Au (Eu + Iu + Su) + 0.3At (Et + It + St) + 0.4Al (El + Il + Sl), where head and neck: 0.1; upper limbs: 0.2; trunk: 0.3; lower limbs: 0.4. Percentage of participants with \>=75 percent (%) reduction from baseline in PASI scores were reported.
Percentage of Participants Achieving Greater Than or Equal to (>=) 125 Percent Increase From Baseline in Psoriasis Area and Severity Index (PASI) Scores	Baseline, Month 1, 3, 6, 12, 24, 36, 48	PASI score is the combined assessment of lesion severity (estimated by 3 components: of erythema, induration and scaling) and area affected into single score range: 0 (no disease) to 72 (maximal disease), with higher scores representing greater severity of psoriasis. Each component of severity, that is, erythema, induration and scaling was assessed separately for four body areas (head and neck \[h\], upper limbs \[u\], trunk \[t\] and lower limbs \[l\]) on a 5-point scale ranging from 0=no involvement, 1=slight, 2=moderate, 3=marked, 4=very marked. Higher score indicates greater severity. Final PASI score = 0.1Ah (Eh + Ih + Sh) + 0.2Au (Eu + Iu + Su) + 0.3At (Et + It + St) + 0.4Al (El + Il + Sl), where head and neck: 0.1; upper limbs: 0.2; trunk: 0.3; lower limbs: 0.4. Percentage of participants with \>=125% increase from baseline in PASI scores were reported.
Number of Participants Who Answered Psoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU)	Baseline, Month 1, 3, 6, 12, 24, 36, 48	Ps-HCRU was a short questionnaire designed to assess healthcare resource use and the impact of psoriasis on work. In the first section, it assessed direct costs associated with healthcare resource use which included participant's interactions with healthcare providers such as general practitioners, dermatologists, cardiologists, gastroenterologists, psychiatrists, surgeons and nurses. When taking the evening dose of tofacitinib, participants were asked to answer the Ps-HCRU questionnaire only if they had an interaction with a healthcare provider or their work was impacted by psoriasis on that specified day. In this outcome measure, number of participants who answered Ps-HCRU at any specified visits were reported.
Psoriasis Area and Severity Index (PASI) Component Scores: Induration	Baseline, Month 1, 3, 6, 12, 24, 36, 48	PASI score is the combined assessment of lesion severity (estimated by 3 components: of erythema, induration and scaling) and area affected into single score range: 0 (no disease) to 72 (maximal disease), with higher scores representing greater severity of psoriasis. Induration was assessed separately for four body areas (head and neck, upper limbs, trunk and lower limbs) on a 5-point scale ranges from 0=no involvement, 1=slight, 2=moderate, 3=marked, 4=very marked. Higher score indicates greater severity.
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores: Erythema at Month 1, 3, 6, 12, 24, 36 and 48	Baseline, Month 1, 3, 6, 12, 24, 36, 48	PASI score is the combined assessment of lesion severity (estimated by 3 components: of erythema, induration and scaling) and area affected into single score range: 0 (no disease) to 72 (maximal disease), with higher scores representing greater severity of psoriasis. Erythema was assessed separately for four body areas (head and neck, upper limbs, trunk and lower limbs) on a 5-point scale ranges from 0=no involvement, 1=slight, 2=moderate, 3=marked, 4=very marked. Higher score indicates greater severity.
Percentage of Participants Achieving Greater Than or Equal to (>=) 50 Percent Reduction From Baseline in Psoriasis Area and Severity Index (PASI) Scores	Baseline, Month 1, 3, 6, 12, 24, 36, 48	PASI score is the combined assessment of lesion severity (estimated by 3 components: of erythema, induration and scaling) and area affected into single score range: 0 (no disease) to 72 (maximal disease), with higher scores representing greater severity of psoriasis. Each component of severity, that is, erythema, induration and scaling was assessed separately for four body areas (head and neck \[h\], upper limbs \[u\], trunk \[t\] and lower limbs \[l\]) on a 5-point scale ranging from 0=no involvement, 1=slight, 2=moderate, 3=marked, 4=very marked. Higher score indicates greater severity. Final PASI score = 0.1Ah (Eh + Ih + Sh) + 0.2Au (Eu + Iu + Su) + 0.3At (Et + It + St) + 0.4Al (El + Il + Sl), where head and neck: 0.1; upper limbs: 0.2; trunk: 0.3; lower limbs: 0.4. Percentage of participants with \>=50% reduction from baseline in PASI scores were reported.
36-Item Short-Form (SF-36) Health Survey Version 2, Acute: Physical Component Summary Scores	Baseline, Month 6, 12, 24, 36, 48	The SF-36 questionnaire, version 2, acute was a 36-item generic health status measure. SF-36 evaluated 8 health-related aspects of an individual: physical functioning, role-physical, bodily pain, social functioning, mental health, role emotional, vitality, and general health. The score range for each of the 8 health aspects ranged from 0 (worst) to 100 (best), with higher scores indicating good health condition. Two summary scale scores were computed from the 8 health aspect scores: physical component summary score and mental component summary score. Score range for both summary scales ranged from 0 (worst) to 100 (best), with higher scores indicating good health condition.
36-Item Short-Form (SF-36) Health Survey Version 2, Acute: Mental Component Summary Scores	Baseline, Month 6, 12, 24, 36, 48	The SF-36 questionnaire, version 2 was a 36-item generic health status measure. SF-36 evaluated 8 health-related aspects of an individual: physical functioning, role-physical, bodily pain, social functioning, mental health, role emotional, vitality, and general health. The score range for each of the 8 health aspects ranged from 0 (worst) to 100 (best), with higher scores indicating good health condition. Two summary scale scores were computed from the 8 health aspect scores: the Physical Component Summary and the Mental Component Summary. Score range for both summary scale ranged from 0 (worst) to 100 (best), with higher scores indicating good health condition.
Number of Participants With Patient Global Assessment (PtGA) Response of "Clear" or "Almost Clear"	Baseline, Month 1, 3, 6, 12, 24, 36, 48	The PtGA evaluated the overall skin disease of participants at that point in time on a single-item. Participants provided their response on a 5-point scale ranges from: 0=clear, 1=almost clear, 2=mild, 3=moderate, 4=severe. Higher score indicated greater severity of disease. Participants who provided their response as "clear (score of 0)" or "almost clear (score of 1)" in PtGA at each specified visit were reported in this outcome measure.
Euro Quality of Life- 5-Dimensions (EQ-5D)-Utility Scores	Baseline, Month 6, 12, 24, 36, 48	EQ-5D: participant rated 5-dimension (mobility, self-care, usual activities, pain and discomfort, and anxiety and depression) questionnaire to assess health-related quality of life in terms of a single utility score. Each dimension was assessed on a 3-point scale (1=no problems, 2=some problems, 3=extreme problems, where higher scores=worse health condition). The responses from the 5 dimensions were used to calculate a single utility index value. Scoring formula developed by EuroQol Group assigned a utility value for each dimension in the profile. Score was transformed and results in a total score range -0.594 to 1.000; higher score indicated a better health state.
Euro Quality of Life-5-Dimensions (EQ-5D)-Visual Analogue Scale Scores (VAS)	Baseline, Month 6, 12, 24, 36, 48	EQ-5D VAS was a participant rated questionnaire to assess health-related quality of life in terms of a single index value. It was a visual analogue scale that ranged from 0 (minimum) to 100 (maximum), with higher scores indicating a better health condition.

Trial Locations

Locations (314): University of Pittsburgh Medical Center
🇺🇸
Pittsburgh, Pennsylvania, United States
Tufts Medical Center
🇺🇸
Boston, Massachusetts, United States
Massachusetts General Hospital - Clinical Unit for Research Trials and Outcomes in Skin
🇺🇸
Boston, Massachusetts, United States
University Hospitals Case Medical Center/Dept. of Dermatology
🇺🇸
Cleveland, Ohio, United States
University Hospitals Case Medical Center
🇺🇸
Cleveland, Ohio, United States
Hautarztpraxis Centrovital
🇩🇪
Witten, Germany
Leavitt Medical Associates of Florida dba Ameriderm Research
🇺🇸
Ormond Beach, Florida, United States
Deaconess Clinic Downtown Research Institute
🇺🇸
Evansville, Indiana, United States
Hamzavi Dermatology
🇺🇸
Fort Gratiot, Michigan, United States
Florida Academic Dermatology Center
🇺🇸
Coral Gables, Florida, United States
Somerset Skin Centre - Dermcenter
🇺🇸
Troy, Michigan, United States
Associates In Research, Inc.
🇺🇸
Fresno, California, United States
Dundee Dermatology
🇺🇸
West Dundee, Illinois, United States
Michigan Center for Research Corporation dba Michigan Center for Skin Care Research
🇺🇸
Clinton, Michigan, United States
Renstar Medical Research
🇺🇸
Ocala, Florida, United States
Park Avenue Dermatology, PA
🇺🇸
Orange Park, Florida, United States
Saint Louis University - Department of Dermatology
🇺🇸
Saint Louis, Missouri, United States
Dermatology Specialists, Inc.
🇺🇸
Oceanside, California, United States
New England Research Associates, LLC
🇺🇸
Trumbull, Connecticut, United States
Miami Research Associates, Inc.
🇺🇸
South Miami, Florida, United States
MedaPhase Inc.
🇺🇸
Newnan, Georgia, United States
Hudson Dermatology
🇺🇸
Evansville, Indiana, United States
Altman Dermatology Associates
🇺🇸
Arlington Heights, Illinois, United States
University of California Irvine
🇺🇸
Irvine, California, United States
Centennial Center-Comprehensive Clinical Research
🇺🇸
Berlin, New Jersey, United States
Advanced Medical Research, Inc.
🇺🇸
Atlanta, Georgia, United States
North Florida Dermatology Associates, PA
🇺🇸
Jacksonville, Florida, United States
Springfield Clinic
🇺🇸
Springfield, Illinois, United States
Wake Dermatology Associates, LLC
🇺🇸
Raleigh, North Carolina, United States
Atlanta Dermatology, Vein & Research Center, P.C.
🇺🇸
Alpharetta, Georgia, United States
Minnesota Clinical Study Center
🇺🇸
Fridley, Minnesota, United States
NorthShore University Health System - Division of Dermatology
🇺🇸
Skokie, Illinois, United States
Dermatology Treatment & Research Center
🇺🇸
Dallas, Texas, United States
Modern Research Associates, PLLC
🇺🇸
Dallas, Texas, United States
Healthcare Partners Medical Group
🇺🇸
Torrance, California, United States
Centro De Investigaciones Dermatologicas
🇦🇷
Caba, Argentina
Schaumburg Dermatology
🇺🇸
Schaumburg, Illinois, United States
Dartmouth-Hitchcock Medical Center-Norris Cotton Cancer Center
🇺🇸
Lebanon, New Hampshire, United States
Rockwood Research Center
🇺🇸
Spokane, Washington, United States
Madison Skin and Research, Inc.
🇺🇸
Madison, Wisconsin, United States
Clinical Science Institute
🇺🇸
Santa Monica, California, United States
Hudklinikken
🇩🇰
Svendborg, Denmark
The Guenther Dermatology Research Centre
🇨🇦
London, Ontario, Canada
CENIT Centro de Neurociencias Investigacion y Tratamiento
🇦🇷
Caba, Argentina
Nemocnice Ceske Budejovice, a.s. Ustavni lekarna
🇨🇿
Ceske Budejovice, Czech Republic, Czechia
Fakultni nemocnice Plzen
🇨🇿
Plzen-Bory, Czechia
SKiN Centre for Dermatology
🇨🇦
Peterborough, Ontario, Canada
Wake Research Associates
🇺🇸
Raleigh, North Carolina, United States
Baker Allergy Asthma and Dermatology Research Center, LLC
🇺🇸
Lake Oswego, Oregon, United States
Bettencourt Skin Center
🇺🇸
Henderson, Nevada, United States
Clinical Partners, LLC
🇺🇸
Johnston, Rhode Island, United States
Dermatology Associates of Knoxville PC
🇺🇸
Knoxville, Tennessee, United States
PMG Research of Wilmington, LLC
🇺🇸
Wilmington, North Carolina, United States
Office of John Michael Humeniuk, MD
🇺🇸
Greer, South Carolina, United States
Center for Clinical Studies
🇺🇸
Webster, Texas, United States
NYU Langone Medical Center, Ambulatory Care Center, Department of Dermatology, Clinical Studies Unit
🇺🇸
New York, New York, United States
MBAL na Voennomeditsinska Akademia
🇧🇬
Sofia, Bulgaria
Menter Dermatology Research Institute
🇺🇸
Dallas, Texas, United States
Central Sooner Research
🇺🇸
Norman, Oklahoma, United States
University of Pittsburgh Medical Center - Department of Dermatology
🇺🇸
Pittsburgh, Pennsylvania, United States
Dr. Glenn and Partners
🇦🇺
Kogarah, New South Wales, Australia
CCA Medical Research
🇨🇦
Ajax, Ontario, Canada
Hôpital Jean Minjoz
🇫🇷
Besancon, France
Virginia Clinical Research, Inc.
🇺🇸
Norfolk, Virginia, United States
Kirk Barber Research
🇨🇦
Calgary, Alberta, Canada
Kozni ordinace
🇨🇿
Praha 1, Czechia
Hautarztpraxis Tegel
🇩🇪
Berlin, Germany
Wenatchee Valley Hospital & Clinics
🇺🇸
Wenatchee, Washington, United States
Universitaetsklinikum Schleswig-Holstein, Campus Kiel
🇩🇪
Kiel, Germany
Universitaetsklinik Carl Gustav Carus
🇩🇪
Dresden, Germany
Hospital da Clinicas da Faculdade de Medicina da Universidade de Sao Paulo
🇧🇷
Sao Paulo, SP, Brazil
Universitaetsklinikum Erlangen Hautklinik im Internistischen Zentrum
🇩🇪
Erlangen, Germany
Aarhus University Hospital
🇩🇰
Aarhus C, Denmark
Chu Morvan
🇫🇷
Brest, Cedex, France
Centre Hospitalier Lyon Sud - Pharmacie
🇫🇷
Pierre Benite, France
Instituto de Dermatologia e Estetica do Brasil LTDA - IDERJ
🇧🇷
Rio De Janeiro, Brazil
Dermadvances Research
🇨🇦
Winnipeg, Manitoba, Canada
Klinika nemoci koznich a pohlavnich
🇨🇿
Hradec Kralove, Czechia
Wiseman Dermatology Research Inc.
🇨🇦
Winnipeg, Manitoba, Canada
University Hospital Center Osijek
🇭🇷
Osijek, Croatia
Stratica Medical
🇨🇦
Edmonton, Alberta, Canada
CHU Limoges - Hôpital Dupuytren - Pharmacie
🇫🇷
Limoges, Cedex, France
Universitaetsklinik und Poliklinik fuer Dermatologie und Venerologie
🇩🇪
Halle, Germany
Universitaetsklinikum Heidelberg
🇩🇪
Heidelberg, Germany
Technischen Universitaet Muenchen
🇩🇪
Muenchen, Germany
The Waterside Clinic
🇨🇦
Barrie, Ontario, Canada
Klinische Forschung Berlin-Mitte GmbH
🇩🇪
Berlin, Germany
Universitaetsklinikum Schleswig-Holstein Campus Luebeck
🇩🇪
Luebeck, Germany
Lynderm Research Inc.
🇨🇦
Markham, Ontario, Canada
HSK, Dr. Horst Schmidt Kliniken GmbH
🇩🇪
Wiesbaden, Germany
Lekarna U sv. Ignace
🇨🇿
Praha 2, Czechia
Hudklinikken Herning
🇩🇰
Herning, Denmark
CHU Jean-Minjoz
🇫🇷
Besancon, France
Hopital Dupuytren
🇫🇷
Limoges, France
Hopital Nord
🇫🇷
Saint Priest En Jarez, France
Facharzt fuer Dermatologie und Allergologie
🇩🇪
Berlin, Germany
Centre de Recherche Dermatologique du Québec Métropolitain
🇨🇦
Québec, Quebec, Canada
Ustanvi lekarna
🇨🇿
Hradec Kralove, Czech Republic, Czechia
Krajska zdravotni a.s.,Masarykovy nemocnice o.z.
🇨🇿
Usti nad Labem, Czechia
Gemeinschaftspraxis Dres.Michael Ockenfels und Christoph Sauter
🇩🇪
Hanau, Germany
Universitaetsklinikum Muenster
🇩🇪
Muenster, Germany
CHU de Nantes - Hotel Dieu
🇫🇷
Nantes Cedex 01, France
CHU De Nice Hopital De L'Archet II
🇫🇷
Nice, France
Universitaets-Hautklinik Eberhard-Karls-Universitaet Tuebingen
🇩🇪
Tuebingen, Baden-wuerttemberg, Germany
Hospital 12 de Octubre
🇪🇸
Madrid, Spain
Klinik and Poliklinik fur Dermatologie and Allergologie der Universitaet Bonn
🇩🇪
Bonn, Germany
Hopital Larrey Departement de Dermatologie
🇫🇷
Toulouse, France
Klinik und Poliklinik fur Dermatologie und Allergologie der Universitaet Bonn
🇩🇪
Bonn, Germany
Grupo Dermatologico De Carolina (Office of Dr. Alma Cruz MD)
🇵🇷
Carolina, Puerto Rico
Seoul National University Hospital
🇰🇷
Seoul, Korea, Republic of
Hospital General Universitario de Alicante
🇪🇸
Alicante, Spain
Hospital Universitario Puerta de Hierro
🇪🇸
Majadahonda, Madrid, Spain
Hospital Universitario Fundacion Alcorcon
🇪🇸
Madrid, Spain
The University of Hong Kong (HKU)-Queen Mary Hospital (QMH)
🇭🇰
Hong Kong, Hong Kong
SZTE Szentgyorgyi Albert Klinikai Kozpont/Borgyogyaszati es Allergologiai Klinika
🇭🇺
Szeged, Hungary
Oddzial Dermatologiczny
🇵🇱
Wroclaw, Poland
Samsung Medical Center
🇰🇷
Seoul, Korea, Republic of
Pharmacy: Sjukhusapoteket Lund
🇸🇪
Lund, Sweden
Karolinska University Hospital- Solna
🇸🇪
Stockholm, Sweden
Whipps Cross University Hospital
🇬🇧
London, United Kingdom
Dept of Dermatology and Venerology of SI "Crimean State Medical University n.a. S.I.Georgiyevskyy"
🇺🇦
Simferopol,, Crimea, Ukraine
Hud kliniken- Skanes Universitetssjukhus i Malmo
🇸🇪
Malmo, Sverige, Sweden
Hospital Universitario La Princesa
🇪🇸
Madrid, Spain
Hudkliniken
🇸🇪
Stockholm, Sweden
eRT
🇬🇧
Peterbrough, United Kingdom
Kantonsspital St. Gallen
🇨🇭
St. Gallen, Switzerland
Chung Shan Medical University Hospital
🇨🇳
Taichung, Taiwan Roc, Taiwan
International Dermatology Research, Inc.
🇺🇸
Miami, Florida, United States
Dawes Fretzin Clinical Research Group, LLC
🇺🇸
Indianapolis, Indiana, United States
MedDerm Associates
🇺🇸
San Diego, California, United States
UCSD Dermatology
🇺🇸
San Diego, California, United States
University of California San Diego
🇺🇸
San Diego, California, United States
Jewish Hospital
🇺🇸
Cincinnati, Ohio, United States
Office of Mark Lee, MD
🇺🇸
San Antonio, Texas, United States
Dermatology Research Associates
🇺🇸
Nashville, Tennessee, United States
University of California San Francisco
🇺🇸
San Francisco, California, United States
Duke University Medical Center
🇺🇸
Durham, North Carolina, United States
Progressive Clinical research, P.A.
🇺🇸
San Antonio, Texas, United States
Stephen Miller, MD, PA
🇺🇸
San Antonio, Texas, United States
Cherry Creek Research, Inc.
🇺🇸
Denver, Colorado, United States
Oregon Dermatology and Research Center
🇺🇸
Portland, Oregon, United States
Oregon Health & Science University
🇺🇸
Portland, Oregon, United States
Radiant Research, Inc.
🇺🇸
Greer, South Carolina, United States
Hopital Saint Louis
🇫🇷
Paris, Lle-de-france, France
CHG Le Mans
🇫🇷
Le Mans, Cedex 09, France
Centre Hospitalier Lyon Sud
🇫🇷
Pierre-Benite, France
C.H.U. de Poitiers la Miletrie
🇫🇷
Poitiers, France
Hôpital Robert Debre
🇫🇷
Reims, France
Hopital de Brabois / Batiment Philippe Canton
🇫🇷
Vandoeuvre les Nancy, France
Horizon Research Group, Inc.
🇺🇸
Mobile, Alabama, United States
UAB Dermatology
🇺🇸
Birmingham, Alabama, United States
Burke Pharmaceutical Research
🇺🇸
Hot Springs, Arkansas, United States
Bakersfield Dermatology and Skin Cancer Medical Group
🇺🇸
Bakersfield, California, United States
The Rockefeller University
🇺🇸
New York, New York, United States
Dermatology Associates
🇺🇸
Wilmington, North Carolina, United States
IP ONLY: University Hospitals Case Medical Center
🇺🇸
Cleveland, Ohio, United States
Rivergate Dermatology Clinical Research Center, PLLC
🇺🇸
Goodlettsville, Tennessee, United States
Arlington Research Center, Inc.
🇺🇸
Arlington, Texas, United States
Suzanne Bruce and Associates, PA
🇺🇸
Houston, Texas, United States
Malvern Diagnostic Imaging
🇦🇺
Malvern, Victoria, Australia
Cliniques Universitaires Saint-Luc
🇧🇪
Brussels, Belgium
Percuro Clinical Research Limited
🇨🇦
Victoria, British Columbia, Canada
Dermatrials Research, Inc.
🇨🇦
Hamilton, Ontario, Canada
Innovaderm Research Inc
🇨🇦
Montreal, Quebec, Canada
Siena Medical Research
🇨🇦
Montreal, Quebec, Canada
CRCMRGilbert Inc., Centre de Dermatologie Maizerets
🇨🇦
Quebec, Canada
Hospital Pablo Tobon Uribe
🇨🇴
Medellin, Antioquia, Colombia
University hospital center "Sestre milosrdnice" clinic for dermatology and venerology disease
🇭🇷
Zagreb, Croatia
Nemocnice Ceske Budejovice,a.s.
🇨🇿
Ceske Budejovice, Czechia
Bispebjerg Hospital, University of Copenhagen
🇩🇰
Copenhagen NV, Denmark
Gentofte Hospital
🇩🇰
Hellerup, Denmark
C.H.U de Reims
🇫🇷
Reims, France
Charité Universitätsmedizin Berlin
🇩🇪
Berlin, Germany
Universitatsklinikum Schleswig-Holstein
🇩🇪
Kiel, Schleswig-holstein, Germany
Klinische Forschung Hamburg GmbH
🇩🇪
Hamburg, Germany
Eberhard-Karls-Universitaet Tuebingen Universitaetshautklinik
🇩🇪
Tuebingen, Germany
"Papageorgiou" General Hospital/B' Dermatology and Venereology Clinic of University of Thessaloniki
🇬🇷
Thessaloniki, Greece
Yonsei University College of Medicine, Severance Hospital
🇰🇷
Seoul, Korea, Republic of
PT&R
🇳🇱
Beek, Netherlands
LKH Feldkirch
🇦🇹
Feldkirch, Austria
Novum Instytut Dermatologii Leczniczej i Estetycznej
🇵🇱
Opole, Poland
Poradnia Dermatologiczna
🇵🇱
Wroclaw, Poland
Rostov-on-Don regional dermatovenerologic dispensary
🇷🇺
Rostov-on-Don, Russian Federation
Dermatovenerologic dispensary #10 of Vyborg region
🇷🇺
Saint-Petersburg, Russian Federation
North-Western State Medical University I.I. Mechnikov
🇷🇺
Saint-Petersburg, Russian Federation
Consorcio Hospital General Universitario de Valencia
🇪🇸
Valencia, Spain
Hermelinen Forskning AB
🇸🇪
Lulea, Sweden
Municipal Institution of health Care
🇺🇦
Kharkiv, Ukraine
Eastern Canada Cutaneous Research Associates Ltd.
🇨🇦
Halifax, Nova Scotia, Canada
Ultranova Skincare
🇨🇦
Barrie, Ontario, Canada
North Bay Dermatology Centre
🇨🇦
North Bay, Ontario, Canada
Co-Medica Research Network Inc.
🇨🇦
Courtice, Ontario, Canada
Oakville Dermatology Laser Centre
🇨🇦
Oakville, Ontario, Canada
Office of Dr. Paul Adam (back-up location)
🇨🇦
Scarborough, Ontario, Canada
Dr. Tuppal's Privat Practice, Oshawa Clinic
🇨🇦
Oshawa, Ontario, Canada
XLR8 Medical Research
🇨🇦
Windsor, Ontario, Canada
K. Papp Clinical Research
🇨🇦
Waterloo, Ontario, Canada
Diex Research Sherbrooke Inc.
🇨🇦
Sherbrooke, Quebec, Canada
Windsor Clinical Research
🇨🇦
Windsor, Ontario, Canada
Salford Royal NHS Foundation Trust
🇬🇧
Salford, Manchester, United Kingdom
Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo
🇧🇷
Sao Paulo, Brazil
Derm Research @888 Inc
🇨🇦
Vancouver, British Columbia, Canada
Reumalab S.A.S.
🇨🇴
Medellin, Antioquia, Colombia
Kobe University
🇯🇵
Kobe, Hyogo, Japan
The Skin Centre
🇨🇦
Vancouver, British Columbia, Canada
Medicity S.A.S
🇨🇴
Bucaramanga, Santander, Colombia
LKH Salzburg, Landesklinik fuer Dermatologie
🇦🇹
Salzburg, Austria
UMHAT "Dr. Georgi Stranski" - II clinical base
🇧🇬
Pleven, Bulgaria
UMBAL-Alexandrovska- Sofia Klinika po dermatologia i venerologia
🇧🇬
Sofia, Bulgaria
Riesgo De Fractura S.A
🇨🇴
Bogota, Cundinamarca, Colombia
University hospital center zagreb
🇭🇷
Zagreb, Croatia
Tampere Univeristy Hospital, Department of Dermatology and Venereology
🇫🇮
Tampere, Finland
Gunma University Hospital
🇯🇵
Maebashi-shi, Gunma, Japan
JR Sapporo hospital
🇯🇵
Sapporo-City, Hokkaido, Japan
Mnogoprofilna Bolnitsa Za Aktivno Lechenie- Tokuda Bolnitsa
🇧🇬
Sofia, Bulgaria
Hospital Clinico Universidad de Chile
🇨🇱
Santiago, Region Metropolitana, Chile
Colegio Mayor de Nuestra Señora del Rosario
🇨🇴
Bogotá, Cundinamarca, Colombia
University General Hospital of Ioannina / Dermatology and Venereology Department
🇬🇷
Ioannina, Greece
Skin And Cancer Foundation
🇦🇺
Melbourne, Victoria, Australia
Dr. Zohair Tomi PMC Inc. Paton Medical Centre
🇨🇦
St. John's, Newfoundland and Labrador, Canada
Nexus Clinical Research
🇨🇦
St. John's, Newfoundland and Labrador, Canada
UHC Sarajevo
🇧🇦
Sarajevo, Bosnia and Herzegovina
UMHAT "Dr Georgi Stranski"
🇧🇬
Pleven, Bulgaria
Enverus Medical Research
🇨🇦
Surrey, British Columbia, Canada
Tsentar za kozhno venericheski zaboliavania EOOD
🇧🇬
Sofia, Bulgaria
Centro Internacional de Estudios Clinicos, CIEC
🇨🇱
Santiago, Region Metropolitana, Chile
Clinica Dermacross S.A.
🇨🇱
Santiago, Region Metropolitana, Chile
Miskolci Semmelweis Korhaz es Egyetemi Oktatokorhaz, Borgyogyaszati Osztaly
🇭🇺
Miskolc, Hungary
Szabolcs-Szatmar-Bereg Megyei Korjazak es Egyetemi Okatokorhaz, Borgyogyaszati Szakrendeles
🇭🇺
Nyiregyhaza, Hungary
ALLERGO-DERM BAKOS Kft.
🇭🇺
Szolnok, Hungary
Vas Megyei Markusovszky Korhaz/Borgyogyaszati Osztaly
🇭🇺
Szombathely, Hungary
NewLab Clinical Research Inc.
🇨🇦
St. John's, Newfoundland and Labrador, Canada
Synexus Magyarorszag Kft.
🇭🇺
Budapest, Hungary
Centro Integral de Reumatologia del Caribe Cicaribe S.A.S
🇨🇴
Barranquilla, Atlantico, Colombia
University Dermatology Clinic "Andreas Syggros" Hospital
🇬🇷
Athens, Attiki, Greece
Debreceni Egyetem Klinikai Kozpont, Borgyogyaszati Klinika
🇭🇺
Debrecen, Hungary
Szabolcs-Szatmar-Bereg Megyei Korhazak es Egyetemi Oktatokorhaz, Klinikai Kutatasi Osztaly
🇭🇺
Nyiregyhaza, Hungary
Veszprem Megyei Csolnoky Ferenc Korhaz Borgyogyaszat
🇭🇺
Veszprem, Hungary
Kumamoto University Hospital
🇯🇵
Kumamoto-city, Kumamoto, Japan
Bacs-Kiskun Megyei Korhaz Szegedi Tudomanyegyetem AOK Oktato Korhaza, Borgyogyaszati Osztaly
🇭🇺
Kecskemet, Hungary
Tolna Megyei Balassa Janos Korhaz, Borgyogyaszati Osztaly
🇭🇺
Szekszard, Hungary
Pecsi Tudomanyegyetem Aok Bor- Nemikortani Es Onkodermatologiai Klinika
🇭🇺
Pecs, Hungary
Instituto Dermatologico De Jalisco "Dr Jose Barba Rubio"
🇲🇽
Zapopan, Jalisco, Mexico
Katedra i Klinika Dermatologii, Wenerologii i Alergologii Akademii Medycznej we Wroclawiu
🇵🇱
Wroclaw, Poland
NZOZ Zdrowie Osteo-Medic
🇵🇱
Bialystok, Poland
Centrum Badan Klinicznych s.c. Wieslawa Porawska, Lukasz Porawski
🇵🇱
Poznan, Poland
Changi General Hospital
🇸🇬
Singapore, Singapore
Krakowskie Centrum Medyczne NZOZ
🇵🇱
Krakow, Poland
Solumed Centrum Medyczne
🇵🇱
Poznan, Poland
Katedra i Klinika Chorob Skornych i Wenerycznych, Pomorski Uniwersytet Medyczny
🇵🇱
Szczecin, Poland
Military Medical Academy N.A. S.M.Kirov
🇷🇺
Saint-Petersburg, Russian Federation
Mexico Centre for Clinical Research S.A. de C.V.
🇲🇽
Mexico, Distrito Federal, Mexico
Centro de Dermatologia de Monterrey
🇲🇽
Monterrey, Nuevo Leon, Mexico
Centro Medico San Lucas
🇲🇽
Monterrey, Nuevo Leon, Mexico
Academisch Medisch Centrum Universiteit van Amsterdam
🇳🇱
Amsterdam, Noord-holland, Netherlands
Spolka Cywilna Andrzej Krolicki, Tomasz Kochanowski "Laser Clinic"
🇵🇱
Szczecin, Poland
MTZ Clinical Research Sp. z o.o.
🇵🇱
Warszawa, Poland
Klinika Dermatologii
🇵🇱
Warszawa, Poland
Uniwersyteckie Centrum Kliniczne
🇵🇱
Gdansk, Pomorskie, Poland
State Research Center of Dermatovenerology,
🇷🇺
Moscow, Russian Federation
Klinika Dermatologii, Wenerologii i Alergologii Uniwersyteckiego Centrum Klinicznego
🇵🇱
Gdansk, Poland
Specjalistyczne Gabinety Lekarskie "Dermed"
🇵🇱
Lodz, Poland
Ryazan regional clinical dermatovenerologic dispensary
🇷🇺
Ryazan, Russian Federation
Clinical hospital of emergency care N.V. Soloviev
🇷🇺
Yaroslavl, Russian Federation
National Skin Centre
🇸🇬
Singapore, Singapore
Oddelenie biologickej liecby, Narodny ustav reumatickych chorob
🇸🇰
Piestany, Slovakia
DOST-Dermatovenerologicke oddelenie sanatorneho typu, SANARE, spol. s r.o.
🇸🇰
Svidnik, Slovakia
Chang Gung Medical Foundation Linkou Branch
🇨🇳
Taoyuan, Taiwan
SI 'Institute for Dermatology and Venerology of AMS of Ukraine'
🇺🇦
Kharkiv, Ukraine
Dept of Dermatology and Venerology of ONMU
🇺🇦
Odessa, Ukraine
Ternopil Regional Municipal Clinical Dermatovenerologic Dispensary
🇺🇦
Ternopil, Ukraine
Zaklad Radiologii Lekarskiej
🇵🇱
Warszawa, Poland
Dermatovenerological dispensary #7
🇷🇺
Moscow, Russian Federation
Chang Gung Medical Foundation Kaohsiung Branch
🇨🇳
Kaohsiung, Taiwan
State Research Center of Dermatovenerology
🇷🇺
Moscow, Russian Federation
Smolensk State Medical Academy
🇷🇺
Smolensk, Russian Federation
Clinical Hospital Center Zvezdara
🇷🇸
Belgrade, Serbia
National Taiwan University Hospital
🇨🇳
Taipei, Taiwan
Military Medical Academy
🇷🇸
Belgrade, Serbia
Department of Dermatology
🇬🇧
Nuneaton, Warwickshire, United Kingdom
Dermatovenerologicka klinika SZU, Fakultna nemocnica s poliklinikou F.D. Roosevelta Banska Bystrica
🇸🇰
Banska Bystrica, Slovakia
Kyiv Oleksandrivska Clin. Hosp., Dermatology department, NMU n.a. O.O. Bogomolets,
🇺🇦
Kyiv, Ukraine
Taipei Medical University-Shuang Ho Hospital
🇨🇳
Taipei, Taiwan
National Cheng Kung University Hospital
🇨🇳
Tainan, Taiwan
Dept of Dermatology and Venerology of Lugansk State Medical University,
🇺🇦
Lugansk, Ukraine
Regional Municipal Dermatovenerologic Dispensary
🇺🇦
Lviv, Ukraine
Universitaetsklinikum Koeln
🇩🇪
Koeln, Germany
Hautarztpraxis Dres. Scholz, Sebastian, Schilling
🇩🇪
Mahlow, Germany
Dres. Kirsten Prepeneit und Volker Streit
🇩🇪
Buchholz, Germany
Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz KoeR
🇩🇪
Mainz, Germany
Universitaetsklinikum Hamburg-Eppendorf
🇩🇪
Hamburg, Germany
MVZ Reichenberger Str., Aerztehaus "Rudolf Virchow"
🇩🇪
Berlin, Germany
Klinikum der Johann Wolfgang Goethe Universitaet
🇩🇪
Frankfurt/Main, Germany
Klinische Forschung Schwerin GmbH
🇩🇪
Schwerin, Germany
New York University (NYU) School of Medicine - Investigational Pharmacy (IP Shipment, Pharmacy)
🇺🇸
New York, New York, United States
Health Concepts
🇺🇸
Rapid City, South Dakota, United States
The Savin Center, P.C.
🇺🇸
New Haven, Connecticut, United States
Olympian Clinical Research
🇺🇸
Tampa, Florida, United States
DermResearch, PLLC
🇺🇸
Louisville, Kentucky, United States
Skin Specialists, P.C
🇺🇸
Omaha, Nebraska, United States
University of North Carolina at Chapel Hill- Hospital
🇺🇸
Chapel Hill, North Carolina, United States
University of North Carolina at Chapel Hill
🇺🇸
Chapel Hill, North Carolina, United States
Piedmont Imaging
🇺🇸
Winston-Salem, North Carolina, United States
PMG Research of Winston-Salem
🇺🇸
Winston-Salem, North Carolina, United States
Triad Dermatology, PA
🇺🇸
Winston-Salem, North Carolina, United States
Wake Forest University Health Sciences
🇺🇸
Winston-Salem, North Carolina, United States
Northwest Dermatology & Laser Centre
🇨🇦
Calgary, Alberta, Canada
Office of Dr. Michael Robern
🇨🇦
Ottawa, Ontario, Canada
Premier Dermatology
🇦🇺
Kogarah, New South Wales, Australia
Dermatology Consulting Services
🇺🇸
High Point, North Carolina, United States
Mountain State Clinical Research
🇺🇸
Bridgeport, West Virginia, United States
Emeritus Research
🇦🇺
Malvern East, Victoria, Australia
Tokyo Yamate Medical Center
🇯🇵
Shinjuku-ku, Tokyo, Japan
Rhode Island Hospital
🇺🇸
Providence, Rhode Island, United States